A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma
- Determine the absorbed radiation doses of CNS lesions after administration of indium In
111 ibritumomab tiuxetan (for imaging) in patients with recurrent primary CNS lymphoma.
- Determine the safety of a therapeutic dose of yttrium Y 90 ibritumomab tiuxetan in
- Determine the radiographic response in patients treated with this drug.
OUTLINE: Patients receive rituximab IV on day 1. Within 4 hours after rituximab
administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes.
Patients then undergo whole body imaging. Patients whose dosimetry indicates that their CNS
lesion would receive a sufficient radioimmunotherapy dose receive a therapeutic dose of
yttrium Y 90 ibritumomab tiuxetan IV over 20-30 minutes on day 7.
Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6
months for 2 years.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Primary Purpose: Treatment
Dosimetry at 1, 24, and 48 hours
Lauren E. Abrey, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan - Kettering Cancer Center||New York, New York 10021|